Filtered By:
Source: Diabetes, Obesity and Metabolism
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 82 results found since Jan 2013.
Observational follow‐up of the PROactive study: a 6‐year update†
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - August 19, 2013 Category: Endocrinology Authors: E. Erdmann, E. Song, R. Spanheimer, A.‐R. van Troostenburg de Bruyn, A. Perez Tags: ORIGINAL ARTICLE Source Type: research
Observational follow‐up of the PROactive Study: a 6‐year update
ConclusionsThese data suggest that improved macrovascular outcomes seen with pioglitazone subside without continued pioglitazone treatment. The double‐blind period bladder cancer imbalance did not persist in follow‐up.
Source: Diabetes, Obesity and Metabolism - July 22, 2013 Category: Endocrinology Authors: Erland Erdmann, Eric Song, Robert Spanheimer, Anne‐Ruth van Troostenburg de Bruyn, Alfonso Perez Tags: Original Paper Source Type: research
Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials
ConclusionsIn type 2 diabetes, the use of sulfonylureas is associated with increased mortality and a higher risk of stroke, whereas the overall incidence of MACE appears to be unaffected. Significant differences in cardiovascular risk could be present in direct comparisons with specific classes of glucose‐lowering agents, such as DPP4 inhibitors, but this hypothesis needs to be confirmed in long‐term cardiovascular outcomes trials. The results of this meta‐analysis need to be interpreted with caution, mainly because of limitations in trial quality and under‐reporting of information on cardiovascular events and mort...
Source: Diabetes, Obesity and Metabolism - May 13, 2013 Category: Endocrinology Authors: M. Monami, S. Genovese, E. Mannucci Tags: ORIGINAL ARTICLE Source Type: research
Cardiovascular Safety Of Sulfonylureas: A Meta‐Analysis Of Randomised Clinical Trials
ConclusionsIn type 2 diabetes, the use of sulfonylureas is associated with increased mortality and a higher risk of stroke, whereas the overall incidence of MACE appears to be unaffected. Significant differences in cardiovascular risk could be present in direct comparisons with specific classes of glucose‐lowering agents, such as DPP4 inhibitors, but this hypothesis needs to be confirmed in long‐term cardiovascular outcomes trials. The results of this meta‐analysis need to be interpreted with caution, mainly because of limitations in trial quality and under‐reporting of information on cardiovascular events and mort...
Source: Diabetes, Obesity and Metabolism - April 22, 2013 Category: Endocrinology Authors: Matteo Monami, Stefano Genovese, Edoardo Mannucci Tags: Original Paper Source Type: research
Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus
ConclusionThese analyses have not shown a signal of increased CV risk with alogliptin in patients with type 2 diabetes. Future results from the adequately powered EXAMINE trial will definitively assess the CV safety profile of aloglipin in patients with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - April 4, 2013 Category: Endocrinology Authors: W. B. White, R. Pratley, P. Fleck, M. Munsaka, M. Hisada, C. Wilson, V. Menon Tags: ORIGINAL ARTICLE Source Type: research
Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus†
ConclusionThese analyses have not shown a signal of increased CV risk with alogliptin in patients with type 2 diabetes. Future results from the adequately powered EXAMINE trial will definitively assess the CV safety profile of aloglipin in patients with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - April 4, 2013 Category: Endocrinology Authors: W. B. White, R. Pratley, P. Fleck, M. Munsaka, M. Hisada, C. Wilson, V. Menon Tags: ORIGINAL ARTICLE Source Type: research
Lower incidence of recorded cardiovascular outcomes in patients with type 2 diabetes using insulin aspart vs. those on human regular insulin: observational evidence from general practices
ConclusionUse of the rapid‐acting insulin analogue aspart was associated with a reduced incidence of macrovascular outcomes in type 2 diabetes in general practices. It is important to confirm this finding in a randomized controlled trial.
Source: Diabetes, Obesity and Metabolism - November 28, 2012 Category: Endocrinology Authors: W. Rathmann, K. Kostev Tags: ORIGINAL ARTICLE Source Type: research
